secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALISADE BIO, INC. (PALI)
CIK:        0001357459
Form:       8-K
Filed at:   2026-08-10T20:18:21+00:00
Accession:  0001357459-26-000017
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palisade Bio reports Q2 2026 net loss $10.6M; advances PALI-2108 into Phase 2
-----------------------------------------------------------------------------

- Q2 2026 net loss $10.6M ($0.05/share) vs $2.8M ($0.58) year ago; R&D spend $7.4M vs $1.7M.
- Cash $125.2M at June 30, 2026; funded through Phase 2 readouts (UC 2H 2027, CD early 2028).
- Phase 1 PALI-2108: 5/5 UC clinical response, 2/5 remission; FSCD SES-CD reduced ~47.5% (3.8 points).
- Phase 2 ASCENTRA-UC enrollment expected 2H 2026; ASCENTRA-CD IND expected 2H 2026, trial start 1Q 2027.
- Board adds Robert Baltera and Jordan Zwick; $0.5M license revenue milestone from Newsoara.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357459/000135745926000017/0001357459-26-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357459/000135745926000017/pali-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001357459-26-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer